Loading
NB
NKGen Biotech, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by CFIC-2015 NV Family Investments, LLC, was filed 02 Jun 2025.
NKGen Biotech, Inc.: what insiders have been doing
Headquartered in United States, NKGen Biotech, Inc. belongs to the Health Care sector and traces its origins to 2017. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of NKGen Biotech, Inc. in twelve months, the latest record being from 2 June 2025.
Since 2021, the database holds 24 purchases and no sales by insiders of the company.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
32
Thresholds
n/a
Buy Volume
€5M
24 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleCFIC-2015 NV Family Investments, LLC1 buy
Paul Y. Song1 buy
Since the insiders bought
- -84.0%Entry US$0.38 · Close at T+365 US$0.06
- -52.1%Entry US$0.17 · Close at T+365 US$0.08
- -86.4%Entry US$3.30 · Close at T+365 US$0.45
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.06
Analyst consensus
Income statement
EBITDA-US$81M
Net income-US$83M0.0% margin
Valuation
Beta0.72
Balance sheet & cash
Market capUS$7.8M
Total debtUS$19.9M
Free Cash Flow-US$22M
Profitability & ownership
ROA-93.3%
% insiders59.0%
% institutions2.1%
Last declaration on 2 June 2025
Declarations32 total
19,669,552 shares@ US$0.1271100.0% of flowCommon StockSEC:0001104659-25-055325:0
Canonical exit: 25 Aug 2025 (T+90)
20,849,725 shares@ US$0.127199.9% of flowCommon StockSEC:0001213900-25-040627:0
Canonical exit: 3 Aug 2025 (T+90)
63,634 shares0Common StockSEC:0001213900-24-112773:0
83,214 shares0Common StockSEC:0001213900-24-111880:1
110,157 shares0Common StockSEC:0001213900-24-111880:2
97,232 shares0Common StockSEC:0001213900-24-111880:0
2,500,000 shares0Common StockSEC:0001209191-23-058901:0
76.06 shares@ US$3.290.0% of flowCommon StockSEC:0001209191-23-057748:1
Canonical exit: 6 Mar 2024 (T+90)
75.3 shares@ US$3.320.0% of flowCommon StockSEC:0001209191-23-057748:0
Canonical exit: 5 Mar 2024 (T+90)
105.17 shares@ US$3.330.0% of flowCommon StockSEC:0001209191-23-057370:1
Canonical exit: 4 Mar 2024 (T+90)
450 shares@ US$3.19Common StockSEC:0001209191-23-057369:1
Canonical exit: 3 Mar 2024 (T+90)
220 shares@ US$3.3596.2% of flowCommon StockSEC:0001209191-23-057369:0
Canonical exit: 29 Feb 2024 (T+90)
162.78 shares@ US$3.070.0% of flowCommon StockSEC:0001209191-23-057370:0
Canonical exit: 3 Mar 2024 (T+90)
140.4 shares@ US$2.850.0% of flowCommon StockSEC:0001209191-23-056768:1
Canonical exit: 25 Feb 2024 (T+90)
103.25 shares@ US$2.910.0% of flowCommon StockSEC:0001209191-23-056768:0
Canonical exit: 25 Feb 2024 (T+90)
13 shares@ US$2.9150.0% of flowCommon StockSEC:0001209191-23-056524:1
Canonical exit: 19 Feb 2024 (T+90)
52.63 shares@ US$2.850.0% of flowCommon StockSEC:0001209191-23-056523:1
Canonical exit: 20 Feb 2024 (T+90)
100 shares@ US$2.800.0% of flowCommon StockSEC:0001209191-23-056523:0
Canonical exit: 19 Feb 2024 (T+90)
10 shares@ US$2.943.8% of flowCommon StockSEC:0001209191-23-056524:0
Canonical exit: 18 Feb 2024 (T+90)
1,773,631 shares0Common StockSEC:0001104659-23-106578:0
20,000 shares0Common StockSEC:0001104659-21-092153:0
3,182 shares@ US$9.90Common StockSEC:0001104659-21-076032:1
Canonical exit: 30 Aug 2021 (T+90)
1,818 shares@ US$9.9061.2% of flowCommon StockSEC:0001104659-21-076032:0
Canonical exit: 26 Aug 2021 (T+90)
22,125 shares0Common StockSEC:0001104659-21-075828:0
320 shares@ US$9.910.0% of flowCommon StockSEC:0001104659-21-073289:1
Canonical exit: 24 Aug 2021 (T+90)
25 of 32 declarations
About NKGen Biotech, Inc.
NKGen Biotech, Inc. is a biopharmaceutical company focused on developing NK cell-based therapies for cancer treatment. It is listed on NASDAQ under the ticker NK.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
